The effect of sunitinib treatment was evaluated by DCE-MRI, intravital microscopy, and immunohistochemistry in pancreatic ductal adenocarcinoma (PDAC) xenografts growing in dorsal window chambers or intramuscularly in the hind leg of mice. Sunitinib selectively removed small-diameter vessels and increased blood flow velocity. The increased blood flow velocity was not sufficient to compensate for the loss of tumor vessels, and, consequently, sunitinib-treated PDAC xenografts showed increased fractions of hypoxic tissue. Ktrans derived by pharmacokinetic analysis of DCE-MRI data was sensitive to microvascular density and hypoxia in both untreated and sunitinib-treated PDAC xenografts.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords